EXTENDED REPORT

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

G J Wolbink^1,4, A E Voskuyl², W F Lems^2,3, E de Groot⁴, M T Nurmohamed⁴, P P Tak⁵, B A C Dijkmans^1,2,3 and L Aarden⁴

¹ Jan van Breemen Institute, Amsterdam, The Netherlands
² VU Medical Centre, Amsterdam, The Netherlands
³ Slotervaart Hospital, Amsterdam, The Netherlands
⁴ Sanquin Research, Amsterdam, The Netherlands
⁵ Academic Medical Centre/University of Amsterdam, Amsterdam, The Netherlands

Correspondence to:
Correspondence to:
Dr G J Wolbink
Dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands; g.wolbink{at}janvanbreemen.nl

Objective: To investigate the relationship between serum trough infliximab levels and clinical response to infliximab treatment in patients with rheumatoid arthritis (RA).

Methods: Disease activity and serum trough infliximab levels before and 2, 6, and 14 weeks after initiation of infliximab treatment at a dose of 3 mg/kg in a cohort of 105 patients with RA were assessed. Serum trough infliximab levels in responders and non-responders were compared. Additionally, the clinical responses of patients with high, intermediate, and low serum trough infliximab levels at 14 weeks were compared.

Results: After 14 weeks of treatment non-responders had lower serum trough levels of infliximab than responders (median (interquartile range) 0.5 (0.2–2.2) v 3.6 (1.4–8.2) mg/l; p<0.01)). Patients with low serum trough infliximab levels at 14 weeks had significantly less improvement in the 28 joint count Disease Activity Score (DAS28) score than patients with intermediate or high serum trough infliximab levels at 14 weeks. Pretreatment C reactive protein (CRP) levels correlated negatively with serum trough infliximab levels at 14 weeks after the start of treatment (Spearman rank correlation r_s = –0.43, p<0.001).

Conclusion: Serum trough levels of infliximab correlate with the clinical response to treatment with infliximab and pretreatment CRP levels. This study indicates that patients with high pretreatment CRP levels might benefit from higher dosages of infliximab or shorter dosing intervals.

Abbreviations: CRP, C reactive protein; DAS28, 28 joint Disease Activity Score; ELISA, enzyme linked immunosorbent assay; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; TNF, tumour necrosis factor

Keywords: C reactive protein; Disease Activity Score; infliximab; rheumatoid arthritis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Bansard, C., Lequerre, T., Daveau, M., Boyer, O., Tron, F., Salier, J.-P., Vittecoq, O., Le-Loet, X. (2009). Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?. Rheumatology (Oxford) 0: kep112v1-kep112 [Abstract] [Full Text]  
• van den Bemt, B J F, den Broeder, A A, Snijders, G F, Hekster, Y A, van Riel, P L C M, Benraad, B, Wolbink, G J, van den Hoogen, F H J (2008). Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 67: 1697-1701 [Abstract] [Full Text]  
• Sekiguchi, N., Kawauchi, S., Furuya, T., Inaba, N., Matsuda, K., Ando, S., Ogasawara, M., Aburatani, H., Kameda, H., Amano, K., Abe, T., Ito, S., Takeuchi, T. (2008). Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-{alpha} monoclonal antibody, infliximab. Rheumatology (Oxford) 47: 780-788 [Abstract] [Full Text]  
• Svenson, M., Geborek, P., Saxne, T., Bendtzen, K. (2007). Monitoring patients treated with anti-TNF-{alpha} biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 46: 1828-1834 [Abstract] [Full Text]  
• Bartelds, G. M, Wijbrandts, C. A, Nurmohamed, M. T, Stapel, S., Lems, W. F, Aarden, L., Dijkmans, B. A C, Tak, P. P., Wolbink, G. J. (2007). Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66: 921-926 [Abstract] [Full Text]  
• Lequerre, T., Jouen, F., Brazier, M., Clayssens, S., Klemmer, N., Menard, J.-F., Mejjad, O., Daragon, A., Tron, F., Le Loet, X., Vittecoq, O. (2007). Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford) 46: 446-453 [Abstract] [Full Text]  
• van der Laken, C J, Voskuyl, A E, Roos, J C, Stigter van Walsum, M, de Groot, E R, Wolbink, G, Dijkmans, B A C, Aarden, L A (2007). Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66: 253-256 [Abstract] [Full Text]  
• Flendrie, M., Creemers, M. C. W., van Riel, P. L. C. M. (2007). Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford) 46: 146-149 [Abstract] [Full Text]  
• Roos, J. C., Ostor, A. J., Okamoto, H., Dentener, M. A., Wouters, E. F.M., Scott, D.L., Kingsley, G.H. (2006). Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis. NEJM 355: 2046-2048 [Full Text]  
• Bartelds, G M, Wolbink, G J, Stapel, S, Aarden, L, Lems, W F, Dijkmans, B A C, Nurmohamed, M T (2006). High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 65: 1249-1250 [Full Text]  
• den Broeder, A A, de Jong, E, Franssen, M J A M, Jeurissen, M E C, Flendrie, M, van den Hoogen, F H J (2006). Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 65: 760-762 [Abstract] [Full Text]